In recent years, several cardiovascular outcome studies to test the safety of glucose-lowering drugs have demonstrated that SGLT2 inhibitors have a potential protective effect against cardiovascular events that is comparable to existing anti-heart failure drugs. This evidence concerns the gene SLC5A2 and heart failure.